Theravance Biopharma, Inc. (TBPH) Balance Sheet

NASDAQ: TBPHAssets, liabilities, debt and equity over 10 years.

TBPH balance sheet, 2025

December 31, 2025 · U.S. dollars

$485.6M assets = $188.8M liabilities + $296.7M equity

What it owns$485.6MCash & ST investments: $315.4M (64.9%)Cash & ST investments$315.4M · 65%Receivables: $95.5M (19.7%)Receivables$95.5M · 20%Other current: $7.6M (1.6%)PP&E: $30.3M (6.2%)PP&E $30.3MLT investments: $11.1M (2.3%)Other non-current: $25.7M (5.3%)=How it is financed$485.6MCurrent liabilities: $38.3M (7.9%)Current liabilities $38.3MOther LT liabilities: $150.5M (31.0%)Other LT liabilities$150.5M · 31%Shareholders’ equity: $296.7M (61.1%)Shareholders’ equity$296.7M · 61%

Both columns are drawn to the same scale: what TBPH owns equals what it owes plus shareholders’ equity. Hover a block for its value.

TBPH financial health

Debt / equity0.25
Low leverage · $0.25 of debt for each $1 of equity
Equity / assets61.1%
Equity-funded · of assets funded by shareholders
Cash / debt417.7%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

TBPH balance sheet trends, 2016–2025

Theravance Biopharma, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$639.3M2016$485.6M2025−3.0%/yr
Total liabilities$289.0M2016$188.8M2025−4.6%/yr
Shareholders’ equity$350.2M2016$296.7M2025−1.8%/yr
Cash & short-term investments$501.1M2016$315.4M2025−5.0%/yr
Total debt$222.7M2016$75.5M2025−11.3%/yr
Net cash (debt)$278.4M2016$239.9M2025−$38.6M
Working capital$479.2M2016$380.2M2025−$99.1M
Book value per share$7.832016$5.762025−3.4%/yr
Debt / equity0.6420160.252025−0.38
Shares outstanding44.7M201651.5M2025+1.6%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

TBPH assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

TBPH liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

TBPH debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

TBPH balance sheet

Theravance Biopharma, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$315.4M$88.3M$102.4M$327.5M$173.5M$292.9M$280.8M$505.3M$348.6M$501.1M
Cash & equivalents$167.8M$37.8M$39.5M$298.2M$90.0M$81.5M$58.1M$378.0M$89.0M$344.7M
Short-term investments$147.6M$50.6M$62.9M$29.3M$83.5M$211.5M$222.8M$127.3M$259.6M$156.4M
Receivables$95.5M$68.4M$17.5M$16.8M$57.6M$69.7M$50.6M$10.7M$7.1M$9.1M
Inventory$0−$68.5M$1$1.5M$10.2M$20.4M$1$1$16.8M$12.2M
Other current assets$7.6M$72.8M$13.6M$7.7M$8.6M$10.4M$7.1M$16.9M$6.2M$6.1M
Total current assets$418.5M$161.1M$133.5M$353.5M$249.9M$393.3M$338.5M$532.8M$378.7M$528.5M
Property, plant & equipment (net)$30.3M$35.8M$45.4M$52.0M$53.3M$59.7M$59.2M$13.2M$10.2M$8.5M
Goodwill & intangible assets$0$0$0$0$0$0$0$0$0$0
Long-term investments$11.1M$0$0$0$67.5M$12.8M$8.7M$11.9M$49.8M$99.6M
Other non-current assets$25.7M$157.3M$203.1M$201.9M$4.1M$3.3M$2.4M$2.4M$2.7M$2.7M
Total assets$485.6M$354.2M$382.0M$607.4M$374.8M$469.1M$408.8M$560.2M$441.4M$639.3M
Liabilities
Accounts payable$2.6M$2.2M$1.5M$1.6M$3.1M$6.8M$4.8M$9.0M$5.9M$1.7M
Short-term debt$10.9M$10.7M$3.9M$6.8M$17.4M$29.2M$17.6M—$223.7M$222.7M
Deferred revenue——−$5.4M$24,000$98,000$11.5M$31.6M$43.4M$125,000$152,000
Total current liabilities$38.3M$32.1M$24.8M$28.7M$58.6M$123.6M$111.7M$98.6M$62.6M$49.3M
Long-term debt$0$0$0$0$228.0M$227.0M$445.2M$454.4M$223.7M$222.7M
Lease obligations$42.7M$49.8M$49.2M$74.1M$52.7M$47.2M$55.5M———
Other long-term liabilities$150.5M$146.5M$144.2M$136.9M$426.8M$422.3M$75.8M$58.9M$39.9M$17.1M
Total liabilities$188.8M$178.6M$169.0M$165.6M$713.4M$772.8M$632.7M$611.8M$326.2M$289.0M
Shareholders' equity
Common stock & paid-in capital$1,000——$1,000$1,000$1,000$1,000$1,000$1,000$1,000
Retained earnings (deficit)−$859.6M−$965.5M−$909.1M−$853.9M−$1.73B−$1.53B−$1.25B−$1.01B−$797.7M−$512.2M
Treasury stock————————$0$0
Accumulated other comprehensive income$61,000$7,000−$64,999−$15,000$0$47,000$145,000−$166,000−$733,000−$253,000
Minority interest————————$0$0
Total shareholders' equity$296.7M$175.5M$213.0M$441.8M−$338.6M−$303.8M−$223.8M−$51.6M$115.2M$350.2M
Key figures
Total debt$75.5M$49.8M$49.2M$52.2M$669.5M$676.3M$510.5M$454.4M$223.7M$222.7M
Net cash (debt)$239.9M$38.5M$53.3M$275.3M−$496.1M−$383.3M−$229.7M$50.9M$124.8M$278.4M
Working capital$380.2M$129.0M$108.8M$324.7M$191.3M$269.8M$226.8M$434.3M$316.2M$479.2M
Tangible book value$296.7M$175.5M$213.0M$441.8M−$338.6M−$303.8M−$223.8M−$51.6M$115.2M$350.2M
Book value per share$5.76$3.59$3.85$6.00−$4.87−$4.87−$4.03−$0.96$2.20$7.83
Shares outstanding51.5M48.8M55.3M73.6M69.5M62.3M55.6M54.0M52.4M44.7M
Current ratio10.935.025.3912.314.263.183.035.416.0510.73
Quick ratio10.734.894.8411.993.942.932.975.245.6910.36
Debt / equity0.250.280.230.12————1.940.64
Equity / assets61.1%49.6%55.8%72.7%−90.3%−64.8%−54.8%−9.2%26.1%54.8%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 23, 2026); data from EODHD.

TBPH financial position

At the end of fiscal 2025 (December 31, 2025), Theravance Biopharma had total assets of $485.6 million (up 37.1% from a year earlier), total liabilities of $188.8 million and shareholders' equity of $296.7 million. It held $315.4 million in cash and short-term investments against $75.5 million of debt, a net cash position of $239.9 million. Its current ratio was 10.93. In the latest quarter (ended June 30, 2026) total assets were $469.8 million and equity $289.7 million.

Related: TBPH income statement, TBPH cash flow statement, TBPH key metrics. See the TBPH stock overview for the latest quote and news.

TBPH balance sheet FAQ

What are Theravance Biopharma's total assets?

Theravance Biopharma reported total assets of $485.6 million at the end of fiscal 2025 (December 31, 2025), compared with $354.2 million a year earlier.

How much debt does Theravance Biopharma have?

Theravance Biopharma had $75.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.25.

How much cash does Theravance Biopharma have?

Theravance Biopharma held $315.4 million in cash and short-term investments at the end of fiscal 2025; with $75.5 million of debt that is net cash of $239.9 million.

What is Theravance Biopharma's book value?

Theravance Biopharma's shareholders' equity (book value) was $296.7 million at the end of fiscal 2025, or $5.76 per share.

What is Theravance Biopharma's current ratio?

Theravance Biopharma had current assets of $418.5 million and current liabilities of $38.3 million, a current ratio of 10.93 (it can cover its short-term obligations).

Biotechnology: balance sheet